Luminex Corporation trades as part of the healthcare sector and is in the medical instruments and equipment industry. The company CEO is Nachum Shamir. Luminex Corp develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its products include MAGPIX, Luminex 100/200, and FLEXMAP 3D.
Previous Intraday Trading Performance:
The LMNX stock showed a previous change of 0.09% with an open at 21.78 and a close of 21.73. It reached an intraday high of 21.79 and a low of 21.46.
The stock has a market cap of $977.4m with 45.0m shares outstanding, of which the float is 41.2m shares. Trading volume reached 223,615 shares compared to its average volume of 287,512 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.
Historical Trading Performance:
Over the last five trading days, Luminex Corporation shares returned 0.79% and in the past 30 trading days it returned -5.93%. Over three months, it changed -9.76%. In one year it has changed -26.70% and within that year its 52-week high was 35.37 and its 52-week low was 20.24. LMNX stock is 7.36% above its 52 Week Low.
Our calculations show a 200 day moving average of 25.37 and a 50 day moving average of 22.15. Currently LMNX stock is trading -14.33% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.
The last annual fiscal EPS for the company was reported at 0.42 that ended on 31st of December 2018, which according to the previous close, that is a PE of 51.74. Based on 5 analyst estimates, the consensus EPS for the next quarter is 0.07. The TTM EPS is 0.49, which comes to a TTM PE of 44.35. Historically, the PE high was 127.60 and the PE low was 16.40. If the stock reached its PE low, that would represent a price of 8.04, which is a decrease of -63.02%.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr of 2019||(Reported on 05/06/2019):||0.07|
|4th||Qtr of 2018||(Reported on 02/04/2019):||-0.05|
|3rd||Qtr of 2018||(Reported on 11/05/2018):||0.04|
|2nd||Qtr of 2018||(Reported on 08/06/2018):||0.13|
|1st||Qtr of 2018||(Reported on 05/07/2018):||0.30|
The dividend per share is currently 0.24, which is a dividend yield of 1.10%. Also, the payout ratio is 48.98%, therefore the dividend is safe according to our calculations.
Base on our calculations, the intrinsic value per share is 12.47, which means it may be overvalued by -74.27%.
Indicators to Watch:
The current calculated beta is 0.80.
SeekingAlpha: Ruby Tuesday board rejects Boaz Group offer
Based on last reported financials, the company’s return on equity is 1.79%, return on assets is 1.58%, profit margin is 2.67%, price-to-sales is 3.15 and price-to-book is 2.08.
All scores are out of six:
1 :Valuation Score
0 :Past Performance Score
6 :Financial Strength Score
4 :Future Growth Score
1 :Dividend Score
2 :Overall Score